New tablet trial aims to repigment vitiligo patches
NCT ID NCT07172347
Summary
This study is testing whether an oral tablet called VC005 can help reduce the white skin patches caused by non-segmental vitiligo, primarily on the face. It will involve about 120 adults and compare the new tablet against a placebo over 24 weeks to see if it's safe and effective. The main goal is to measure how much the facial vitiligo area shrinks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Peking University People's Hospital
RECRUITINGBeijing, Beijng, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.